Weixinkang Pharmaceutical was established in 2002, officially founded in 2006, formally renamed Tibet Weixinkang Pharmaceutical Co., Ltd. in 2013, and listed on the mainboard of the Shanghai Stock Exchange (stock code 603676.SH) in 2017. The company now has 11 branches and subsidiaries and nearly 800 employees. Guided by clinical needs, the company focuses on the R&D and innovation of generic and innovative drugs. Weixinkang is a comprehensive high-tech medical enterprise integrating medicine R&D, production, and sales. The company has significant advantages in intravenous vitamins, intravenous trace elements, and intravenous electrolytes.
The major products of the company include Multivitamin For Injection (12), Multivitamins For Injection (13)(10/3)，Pediatric Multivitamins For Injection (13), Concentrate Of Trace Elements Solution for Infusion, Compound Amino Acid Injection (20AA), Pediatric Compound Amino Acid Injection (19AA-I), Acetylcysteine Solution For Inhalation, Potassium Aspartate and Magnesium Aspartate Injection, Iron Sucrose Injection, Multiple Electrolytes Injection (II), Multiple Electrolytes Injection (V), and Carbohydrate Electrolyte Injection.
The company has established a professional and efficient market sales network, with a business system covering over 3,000 second-tier and above medical institutions and mainstream commercial channels across the country and most provinces.
The "people-oriented and excellence-driven" talent philosophy of Weixinkang has attracted many professionals and laid a solid talent foundation for the company's long-term development. With firm roots in China and visions for global expansion, Weixinkang will continue to adhere to the mission of "good health and well-being" by focusing on health services and new research frontiers, following the development trend of the pharmaceutical industry, and continuously strengthening innovative and technological capacities in order to provide more innovative and accessible treatment options for patients worldwide. Weixinkang strives to become a leading generic and innovative drug manufacturer in the modernized, scaled up high-tech pharmaceutical industry.
